Your browser doesn't support javascript.
loading
Development of immunity-related adverse events correlates with baseline clinical factors, survival and response to anti-PD-1 treatment in patients with inoperable or metastatic melanoma.
Cybulska-Stopa, Bozena; Zietek, Marcin; Czarnecka, Anna M; Piejko, Karolina; Dziura, Robert; Galus, Lukasz; Ziólkowska, Barbara; Kieszko, Stanislaw; Kempa-Kaminska, Natasza; Calik, Jacek; Seredynska, Joanna; Gadek, Kamila; Zemelka, Tomasz; Teterycz, Pawel; Kubiatowski, Tomasz; Suwinski, Rafal; Mackiewicz, Jacek; Rutkowski, Piotr.
Afiliação
  • Cybulska-Stopa B; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Zietek M; Department of Oncology, Wroclaw Medical University, Wroclaw, Poland.
  • Czarnecka AM; Department of Surgical Oncology, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland.
  • Piejko K; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Dziura R; Department of Experimental Pharmacology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
  • Galus L; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Ziólkowska B; Clinical Oncology Department, Holy Cross Cancer Center, Kielce, Poland.
  • Kieszko S; Department of Medical and Experimental Oncology, University of Medical Sciences, Poznan, Poland.
  • Kempa-Kaminska N; Chemotherapy Department, Greater Poland Cancer Centre, Poznan, Poland.
  • Calik J; II Clinic of Radiotherapy and Chemotherapy, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.
  • Seredynska J; Department of Clinical Oncology, Saint Jan of Dukla Oncology Centre of the Lublin Region, Lublin, Poland.
  • Gadek K; Department of Clinical Oncology, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland.
  • Zemelka T; Department of Clinical Oncology, Wroclaw Comprehensive Cancer Center, Wroclaw, Poland.
  • Teterycz P; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Kubiatowski T; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Suwinski R; Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Cracow Branch, Poland.
  • Mackiewicz J; Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
  • Rutkowski P; Department of Clinical Oncology, Saint Jan of Dukla Oncology Centre of the Lublin Region, Lublin, Poland.
J Dermatolog Treat ; 33(4): 2168-2174, 2022 Jun.
Article em En | MEDLINE | ID: mdl-34057374
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Dermatolog Treat Assunto da revista: DERMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Polônia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Observational_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: J Dermatolog Treat Assunto da revista: DERMATOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Polônia